Related Experiment Videos
Irinotecan in cervical cancer
J J Kavanagh1, C F Verschraegen, A P Kudelka
1Section of Gynecologic Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas, USA.
Oncology (Williston Park, N.Y.)
|September 3, 1998
Summary
Irinotecan shows limited efficacy (13-20% response) for recurrent cervical cancer. Gastrointestinal toxicity is a concern, but combinations with cisplatin warrant further investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cervical cancer recurrence presents treatment challenges.
- Irinotecan (CPT-11) is a topoisomerase inhibitor evaluated for refractory/recurrent cervical cancer.
Purpose of the Study:
- To review existing studies on irinotecan for cervical cancer.
- To assess irinotecan's efficacy and toxicity, including combination therapies.
Main Methods:
- Review of multiple studies on irinotecan (CPT-11) in cervical cancer.
- Analysis of response rates and toxicities from various treatment schedules.
- Inclusion of Phase I study data for irinotecan and cisplatin combination.
Main Results:
- Response rates for irinotecan ranged from 13% to 20%.
- Hematologic and gastrointestinal toxicities were observed.
- Gastrointestinal toxicity was a significant issue.
Conclusions:
- Irinotecan demonstrates modest efficacy in refractory/recurrent cervical cancer.
- Further research into irinotecan combinations, especially with cisplatin, is recommended.